Intersect ENT

Intersect ENT is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The Company markets the first and only drug-releasing sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
Company Growth (employees)
Type
Public
HQ
Menlo Park, US
Founded
2003
Size (employees)
303 (est)+11%
Intersect ENT was founded in 2003 and is headquartered in Menlo Park, US

Key People at Intersect ENT

Lisa Earnhardt

Lisa Earnhardt

President & CEO
Monika De Martini

Monika De Martini

CFO
Robrt Binney

Robrt Binney

Vice President of Sales
Amy Couel wolbeck

Amy Couel wolbeck

Vice President, Regulatory Affairs and Quality
Susan P Stimson

Susan P Stimson

Vice President of Marketing
Rich Kaufman

Rich Kaufman

Senior Vice President and Chief Operating Officer

Intersect ENT Office Locations

Intersect ENT has an office in Menlo Park
Menlo Park, US (HQ)
1555 Adams Dr

Intersect ENT Data and Metrics

Intersect ENT Financial Metrics

Intersect ENT's revenue was reported to be $78.7 m in FY, 2016 which is a 28% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

78.7 m

Revenue growth (FY, 2015 - FY, 2016), %

28%

Gross profit (FY, 2016)

65.7 m

Gross profit margin (FY, 2016), %

83%

Net income (FY, 2016)

(25.2 m)

EBIT (FY, 2016)

(26.1 m)

Market capitalization (25-May-2017)

690.5 m

Closing share price (25-May-2017)

23.8

Cash (31-Dec-2016)

9.9 m
Intersect ENT's current market capitalization is $690.5 m.
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Revenue

38.6 m61.6 m78.7 m

Revenue growth, %

60%28%

Cost of goods sold

10.2 m12.3 m13 m

Gross profit

28.4 m49.3 m65.7 m

Gross profit Margin, %

74%80%83%

Operating expense total

46.4 m76.2 m91.8 m

EBIT

(18.1 m)(26.9 m)(26.1 m)

EBIT margin, %

(47%)(44%)(33%)

Net Income

(18.4 m)(26.6 m)(25.2 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Cash

13.4 m34.8 m9.9 m

Accounts Receivable

8.3 m11.5 m14.4 m

Inventories

951 k1.5 m1.3 m

Current Assets

60.3 m141.2 m125.3 m

PP&E

1.5 m3.2 m4.1 m

Total Assets

63 m144.6 m129.8 m

Accounts Payable

2.1 m1.9 m3.3 m

Current Liabilities

8.1 m13.1 m14.4 m

Additional Paid-in Capital

150.4 m253.5 m262.9 m

Retained Earnings

(96.6 m)(123.3 m)(148.5 m)

Total Equity

53.8 m130.2 m114.4 m

Financial Leverage

1.2 x1.1 x1.1 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(18.4 m)(26.6 m)(25.2 m)

Accounts Receivable

(4.1 m)(3.1 m)(3 m)

Inventories

(541 k)(544 k)(1.7 m)

Accounts Payable

645 k(230 k)1.2 m

Cash From Operating Activities

1.1 m21.4 m(20.1 m)

Purchases of PP&E

(367 k)(1.5 m)(2.1 m)

Cash From Investing Activities

(35.5 m)(56.7 m)(6.9 m)

Cash From Financing Activities

54.6 m98.2 m2 m
Y, 2016

Financial Leverage

1.1 x

Intersect ENT Operating Metrics

FY, 2016

Patients Served

150 k

Patents Issued

77

Facilities

1

Trademarks Pending

35

Patents (US)

30

Trademarks

29

Products

2

Accounts

2.4 k

Patents Pending

37

Trademarks (US)

4

Intersect ENT Market Value History

Intersect ENT Online and Social Media Presence

Intersect ENT Company Life and Culture

You may also be interested in